GERON CORP
GERNNasdaq
$1.44
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↑ +13.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$963,900.00
Enterprise Value
$51.9M
P/E
—
P/S
—
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$67.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-29.4%
ROIC
-14.6%
Debt / Equity
0.5
Net Cash
-$50.9M
Return 1Y
+11.6%
Company profile
Geron Corporation focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials. The company was incorporated in 1990 and is headquartered in Foster City, California.
- CEO
- John A. Scarlett
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- California
- Website
- geron.com
Management & directors
- Robertson MichelleEVP, CHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
GERN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$51.8M↑ +30.9%
Diluted EPS-$0.01↓ -66.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $253,000.00 | $1.4M | $596,000.00 | $237,000.00 | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$76.9M | -$114.0M | -$138.6M | -$193.9M | -$173.7M | -$68.6M |
| Net income | -$75.6M | -$116.1M | -$141.9M | -$184.1M | -$174.6M | -$83.5M |
| Diluted EPS | -$0.28 | -$0.35 | -$0.37 | -$0.32 | -$0.27 | -$0.13 |
| Operating cash flow | -$66.7M | -$95.6M | -$127.4M | -$167.7M | -$218.6M | -$111.0M |
| Free cash flow | -$67.1M | -$95.8M | -$127.8M | -$168.6M | -$219.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -30400.4% | -8183.7% | -23246.6% | -81832.9% | — | — |
| Net margin | -29888.1% | -8335.4% | -23808.9% | -77690.7% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $882,000.00 | $28.3M | — | $39.6M | $49.0M | $47.2M | — | $51.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$69.3M | -$28.2M | -$20.1M | -$16.7M | -$12.5M | -$13.9M | -$25.5M | $158,000.00 |
| Net income | -$67.4M | -$26.4M | -$25.4M | -$19.8M | -$16.4M | -$18.4M | -$28.9M | -$3.6M |
| Diluted EPS | -$0.10 | -$0.04 | -$0.04 | -$0.03 | -$0.02 | -$0.03 | -$0.05 | -$0.01 |
| Operating cash flow | -$53.5M | -$58.9M | -$43.9M | -$48.0M | -$27.4M | -$13.6M | -$22.1M | -$62.9M |
| Free cash flow | -$53.7M | -$58.9M | -$44.1M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -7860.9% | -99.8% | — | -42.2% | -25.4% | -29.4% | — | 0.3% |
| Net margin | -7639.8% | -93.5% | — | -50.1% | -33.4% | -39.0% | — | -7.0% |
Company news
Jul 14, 2026
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Spiegel Robert J. | Award | 6,103 | $1.28 | $7,811.84 | filing |
| 2026-03-31 | Spiegel Robert J. | Award | 5,243 | $1.49 | $7,812.07 | filing |
| 2026-02-18 | ROBERTSON MICHELLE· EVP, CHIEF FINANCIAL OFFICER | Sale | 9,855 | $1.94 | $19,118.70 | filing |
| 2026-02-18 | ROBERTSON MICHELLE· EVP, CHIEF FINANCIAL OFFICER | Option exercise | 27,500 | $0.00 | $0.00 | filing |
| 2025-12-31 | Spiegel Robert J. | Award | 5,918 | $1.32 | $7,811.76 | filing |
| 2025-09-30 | Spiegel Robert J. | Award | 5,702 | $1.37 | $7,811.74 | filing |
| 2025-06-30 | Spiegel Robert J. | Award | 5,540 | $1.41 | $7,811.40 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.